SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.880
+0.620 (19.02%)
At close: Nov 1, 2024, 4:00 PM
3.620
-0.260 (-6.70%)
After-hours: Nov 1, 2024, 5:27 PM EDT

Company Description

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases.

It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.

The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma.

In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes.

Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza.

SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

SAB Biotherapeutics, Inc.
SAB Biotherapeutics logo
Country United States
Founded 2014
Industry Biotechnology
Sector Healthcare
Employees 57
CEO Samuel Reich

Contact Details

Address:
777 W 41st St., Suite 401
Miami Beach, Florida 33140
United States
Phone 605 679 6980
Website sabbiotherapeutics.com

Stock Details

Ticker Symbol SABS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001833214
CUSIP Number 78397T103
ISIN Number US78397T2024
Employer ID 85-3899721
SIC Code 2836

Key Executives

Name Position
Samuel J. Reich Chief Executive Officer and Executive Chairman
Dr. Eddie Joe Sullivan Ph.D. Co-Founder, President and Director
Christine E. Hamilton M.B.A. Co-Founder and Independent Director
Dr. Christoph Bausch M.B.A., Ph.D. Executive Vice President and Chief Operating Officer
Dr. Alexandra Kropotova M.B.A., M.D. Executive Vice President and Chief Medical Officer
Dr. Edward D. Hamilton D.V.M. Co-Founder and Board Observer
Mark W. Conley Interim Chief Financial Officer
Dr. Carlos N. Carillo Ph.D. Senior Vice President of Regulatory Affairs

Latest SEC Filings

Date Type Title
Sep 9, 2024 8-K Current Report
Aug 12, 2024 S-8 Securities to be offered to employees in employee benefit plans
Aug 8, 2024 10-Q Quarterly Report
Jul 31, 2024 8-K Current Report
Jun 27, 2024 8-K Current Report
May 31, 2024 8-K Current Report
May 30, 2024 DEF 14A Other definitive proxy statements
May 21, 2024 8-K Current Report
May 20, 2024 10-Q Quarterly Report
May 15, 2024 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB